You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
浙江醫藥(600216.SH):蘋果酸奈諾沙星膠囊獲得藥物臨牀試驗批准通知書

格隆匯3月30日丨浙江醫藥(600216.SH)公佈,公司收到國家藥品監督管理局核准簽發的蘋果酸奈諾沙星膠囊《藥物臨牀試驗批准通知書》,同意開展用於評價蘋果酸奈諾沙星膠囊治療單純性尿路感染的有效性與安全性的多中心、隨機、雙盲、左氧氟沙星平行對照的III期臨牀研究。

蘋果酸奈諾沙星膠囊為我司獨家生產的1類創新藥,為新一代無氟喹諾酮類抗感染藥物,對臨牀常見的大部分革蘭陽性菌、革蘭陰性菌和非典型病原菌均具有良好的抗菌活性。已批准的適應症為治療對奈諾沙星敏感的由肺炎球菌、金黃色葡萄球菌、流感嗜血桿菌、副流感嗜血桿菌、卡他莫拉菌、肺炎克雷伯菌以及肺炎支原體、肺炎衣原體和嗜肺軍團菌所致的輕、中度成人(≥18歲)社區獲得性肺炎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account